Blog

Company Advances Roadmap Ahead of Schedule; Expands Blockchain Applications Beyond Ticketing to Accreditation in Education and Healthcare

NEW YORK, NY AND TORONTO, ON / ACCESS Newswire / October 21, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:1SS), an AI-first technology company specializing in event management, 3D modeling, and spatial computing, is pleased to announce the launch of its Blockchain Ticketing Platform powered by Ethereum, with support for Coinbase Wallet and MetaMask.

This launch accelerates the Company’s previously announced two-track blockchain strategy, which included:

• Phase 1: a custodial wallet solution targeted for Q4 2025; and

• Phase 2: a self-custody personal wallet option originally planned for early 2026.

Thanks to Nextechs3d.ai recent acquisition of Eventdex which had already developed a personal wallet architecture, the Company is now launching the personal wallet first, ahead of schedule. This milestone strengthens Nextech3D.ai’s position as a leader in AI-driven and blockchain-secured event technology.

Secure, Decentralized Ticketing on Ethereum

The new blockchain ticketing platform enables event organizers and attendees to issue, store, and verify tickets as Ethereum-based tokens, seamlessly connected to Coinbase and MetaMask wallets. These blockchain-integrated tickets are:

• Fraud-Resistant: Immutable, traceable smart contracts eliminate duplication and counterfeit risks.

• Programmable: Organizers can embed VIP access, sponsor perks, or resale royalties directly into each ticket.

• Interoperable: Works across Ethereum-based wallets and decentralized applications.

“This launch marks a major leap forward in the event industry,” said Evan Gappelberg, CEO of Nextech3D.ai. “By combining blockchain security, wallet interoperability, and AI-driven event automation, we’re creating a frictionless ecosystem for organizers, exhibitors, and attendees. It’s not just about ticketing-it’s about trust, transparency, and value.”

Beyond Ticketing: Blockchain Accreditation

While blockchain ticketing is the first application, Nextech3D.ai sees enormous potential to extend this technology into blockchain-based accreditation and credentialing-particularly for the Company’s continuing education clients in healthcare, higher education, and professional certification.

Using the same Ethereum infrastructure, Nextech3D.ai will enable event and education customers to issue verifiable, on-chain certificates that prove attendance, accreditation, and achievement-all easily stored and shared through blockchain wallets like Coinbase and MetaMask.

“Our education and healthcare partners are already using our platforms to manage continuing education and compliance programs,” added Gappelberg. “With blockchain accreditation, we’re turning those records into verifiable digital assets-giving institutions and participants a secure, permanent record of professional growth.”

AI + Blockchain: The Future of Event and Education Technology

Nextech3D.ai’s AI Event Suite now includes:

• AI Matchmaking: Intelligent, data-driven networking to connect attendees and exhibitors.

• AI Event Assistant: A real-time, multilingual event concierge available 24/7.

• Blockchain Ticketing: Decentralized ticketing and accreditation on Ethereum with Coinbase and MetaMask wallet support.

This integrated approach positions Nextech3D.ai to lead the convergence of AI, blockchain, and automation in global event and education markets, a sector representing multi-billion-dollar opportunities.

The company has entered into agreements (the “Agreements“) with certain service providers of the Company pursuant to which the Company proposes to issue an aggregate of 3,688,218 common shares at a deemed price of Cdn$ 0.19 per share in consideration of past services and satisfaction of outstanding indebtedness

The share issuances remain subject to the approval of the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About Nextech3D.ai

Nextech3D.ai (OTCQX: NEXCF | CSE: NTAR | FSE: 1SS) is an AI-first technology company developing advanced solutions for event management, 3D modeling, and spatial computing. Through its flagship Map D and Eventdex platforms, Nextech3D.ai powers thousands of events annually with interactive floor mapping, registration, ticketing, mobile apps, AI matchmaking, and now, blockchain ticketing and accreditation.

For further information, please visit: www.Nextech3D.ai.

Investor Relations: investors@nextechar.com

Sign up for Investor News and Info – Click Here

Evan Gappelberg / CEO and Director
866-ARITIZE (274-8493)

Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws

SOURCE: NexTech3D.AI Corp

View the original press release on ACCESS Newswire

National awards spotlight innovation, leadership, and impact across Canada’s digital economy

TORONTO, ON / ACCESS Newswire / October 21, 2025 / Canada’s leading technology executives will be recognized this month at the 2025 CanadianCIO of the Year Awards, honouring the CIOs and CISOs driving transformation and resilience across the country.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / SMX (Security Matters) Public Limited Company (NASDAQ:SMX)(NASDAQ:SMXWW) (the “Company”), today announced that the reverse stock split of the Company’s ordinary shares will begin trading on an adjusted basis giving effect to the reverse stock split on November 18, 2025 under the existing ticker symbol “SMX”. The new CUSIP number of the Company’s ordinary shares will be G8267K307 and the new ISIN code will be IE000UPDVNX9.

On May 2, 2025, the Company’s Shareholders approved a proposal to amend the Company’s constitution to allow the Company’s Board of Director’s to consolidate and/or divide all or any of the Company’s classes of shares as the Board of Directors sees fit. As such, Shareholder approval was not required to effect the reverse stock split.

The Company’s Board of Directors’ fixed the split ratio at 8:1, every 8 ordinary shares of the Company with a nominal value of $0.00000000000312817946 per share will be automatically combined into one (1) ordinary share with a nominal value of $0.00000000002502543568 per share. This will reduce the number of outstanding ordinary shares of the Company from 8,404,581 pre-reverse stock split to 1,050,572 post-reverse stock split.

Outstanding Company options, warrants and other applicable convertible securities, including the Company’s warrants listed on the Nasdaq Capital Market under the symbol SMXWW which will retain its existing CUSIP number, will be proportionately adjusted in accordance with their respective terms. No fractional shares will be issued in connection with the reverse stock split. Instead, the Company will aggregate the fractional entitlements of shareholders who otherwise would be entitled to receive fractional shares because they hold a number of ordinary shares not evenly divisible by 8ordinary shares pursuant to the reverse stock split or they hold less than the number of ordinary shares which should be consolidated into one ordinary share pursuant to the reverse stock split and, to the extent possible, sell such aggregated fractional ordinary shares on the basis of prevailing market prices at such time.

Continental Stock Transfer & Trust Company is acting as exchange agent for the reverse stock split and will send instructions to any shareholders of record who hold stock certificates regarding the exchange of certificates. Shareholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the impact of the reverse stock split reflected in their accounts on or after November 19, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information. Continental Stock Transfer may be reached for questions at (212) 509-4000.

-Ends-

For further information contact:

SMX GENERAL ENQUIRIES
E: info@securitymattersltd.com

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example, the Company’s ability to regain compliance with applicable Nasdaq standards or comply with the continued listing standards of Nasdaq even if the Company regains compliance. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

MDaudit joins AHIMA^® and CWP in a landmark digital series spotlighting the critical role of health information in shaping the future of healthcare

WELLESLEY, MA / ACCESS Newswire / October 21, 2025 / MDaudit, an award-winning cloud-based continuous risk monitoring platform for RCM that enables the nation’s premier healthcare organizations to minimize billing risks and maximize revenues, joins the American Health Information Management Association^® (AHIMA) in a dynamic film series that shines a light on the vital work of health information (HI) professionals at the intersection of care, technology, and policy. Health Information: Making Every Patient’s Story Matter showcases how HI professionals safeguard sensitive data, improve patient outcomes, and shape smarter and more connected healthcare systems through a series of short films, expert interviews, and real-world case studies.

Revenue Integrity and Care Quality

Produced in partnership with strategic content creator Content With Purpose (CWP) and available to stream online, the series features two films from MDaudit. The first is a short documentary that examines how healthcare professionals at Las Vegas-based Renown Health, Nevada’s largest not-for-profit integrated healthcare network, utilize MDaudit’s billing compliance and revenue integrity platform to prevent fraud, waste, and abuse, ensuring appropriate reimbursement and improving care quality.

The second is an interview with MDaudit CEO Ritesh Ramesh, who shares insights into why some hospitals and health networks with strong profit margins can reinvest capital back into new and existing facilities to expand access and offer exceptional patient care despite surging denial rates. These provider organizations tend to invest in advanced revenue cycle management (RCM) technologies, including AI and automation, to accelerate and improve the processing of health information, achieve revenue integrity, and optimize clinical and administrative operations. This, in turn, provides the financial sustainability necessary to expand provider organizations’ services and service footprint, including into traditionally underserved areas.

“The ability to avoid denials and optimize operations and reimbursements by implementing a pre-emptive continuous risk monitoring strategy within RCM is a significant advantage for high-performing healthcare organizations,” says Ramesh. “MDaudit plays an essential role in achieving proactive revenue integrity by helping healthcare organizations balance accurate revenue capture with risk mitigation, enabling confident reinvestment in the future of patient care.”

Revolutionizing Health Data

Filmed across North America, Health Information: Making Every Patient’s Story Matter highlights the innovation, expertise, and collaboration that drive excellence in the profession. It explores themes such as:

• Data for Better Health – how patient data powers improved health outcomes and a deeper understanding of social determinants of health.

• Emerging Technologies – the role of AI and digital tools in enabling accurate, secure, and accessible records.

• Collaboration & Thought Leadership – how partnerships across governments, academia, and industry strengthen health systems.

• Skills, Integrity & Certification – the value of credentials and professional standards in advancing healthcare transformation.

Together, these stories bring the HI profession to center stage, demonstrating how health information is revolutionizing the way data is created, exchanged, and utilized across healthcare. Explore the series here.

About MDaudit

MDaudit is an award-winning AI-enhanced continuous risk monitoring platform and trusted revenue integrity partner to healthcare organizations nationwide. Working in the background, we deliver the insights you need to face the future with confidence. Our sustainable solution enables teams to achieve more with less, driving an efficient and compliant revenue cycle in a rapidly evolving environment. Learn more at www.mdaudit.com

###

Media Contact:

Rachel Driskell | Email

SOURCE: MDaudit

View the original press release on ACCESS Newswire

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir’s foundation for partnerships, licensing, and long-term value creation.

MIAMI, FLORIDA / ACCESS Newswire / October 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced that it has executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., securing worldwide rights to its lead investigational therapy, Telomir-1.

The transaction aligns Telomir’s U.S. rights with TELI’s ex-U.S. intellectual property portfolio, which includes filings across Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates-creating a single global owner positioned to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related diseases.

Under the LOI, each outstanding share of TELI common stock will be exchanged for shares of TELO common stock, with the exchange ratio determined by an independent valuation. The transaction also includes up to $5 million in potential contributions, in cash or cash equivalents, from certain TELI shareholders over the duration of the collaboration – $1 million at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation – providing additional funding to advance development of Telomir-1. The transaction is subject to shareholder approval.

Why Worldwide Rights Expand Value

• Global oncology spend is accelerating: Cancer medicine spending reached $223 billion in 2023 and is projected to reach ~$409 billion by 2028; the U.S. represented roughly 45 percent ($99 billion in 2023) – meaning ex-U.S. markets now account for the majority of global oncology spend (IQVIA Global Oncology Trends 2024).

• Age-related and metabolic markets add further upside: The age-related macular degeneration (AMD) drug market totaled $10.8 billion in 2023 and is projected to grow to ~$18 billion by 2030 (Grand View Research 2024). Meanwhile, the global economic cost of diabetes, dementia, and neurodegenerative disease exceeds $2 trillion annually and continues to rise (IDF Diabetes Atlas 2023; Alzheimer’s Disease International 2023).

• Investor takeaway: With worldwide rights, Telomir can now pursue global or regional partnerships, out-licensing, or asset-sale opportunities across markets where ex-U.S. demand exceeds U.S. demand – enhancing strategic flexibility and long-term enterprise value.

CEO Commentary

Erez Aminov, Chief Executive Officer of the Company, stated:

“Executing this binding LOI to secure worldwide rights transforms Telomir-1 from a U.S.-focused asset into a global platform. Strategically, it gives us cleaner access to partnership, licensing, or even asset sale opportunities across continents. Economically, the addressable market outside the United States is larger than inside it. We believe this unified structure positions Telomir for significant long-term value creation as we continue advancing our epigenetic and longevity programs.”

Dr. Itzchak Angel, Chief Scientific Advisor of the Company, added:

“This global alignment enables us to plan development for true worldwide impact. It streamlines our path to explore Telomir-1 in oncology, metabolic, and degenerative diseases such as breast and pancreatic cancer, AMD, Progeria, Wilson’s disease, and Type 2 diabetes, where our preclinical data already show compelling functional restoration.”

Scientific and Market Context

Telomir-1 is an investigational oral small-molecule epigenetic therapy designed to reset abnormal DNA methylation patterns, stabilize telomeres, and restore proper gene regulation – addressing the root biological causes of cancer, aging, and degenerative disease rather than their downstream symptoms.

Across multiple preclinical models, Telomir-1 has shown activity at the intersection of epigenetic control, DNA methylation balance, telomere maintenance, metal regulation, and mitochondrial health – five cellular processes central to both oncologic and age-related disorders.

Representative findings include:

• Oncology:

  • In triple-negative breast (TNBC) and pancreatic cancer models, Telomir-1 produced a dose dependent loss of cancer-cell viability through iron-dependent mitochondrial and energy-pathway modulation.

  • In prostate cancer, Telomir-1 reversed abnormal DNA methylation of tumor suppressor genes MASPIN, RASSF1A, and STAT1, reactivating natural anti-metastatic defenses.

• Age-Related Macular Degeneration (AMD): Telomir-1 restored retinal structure and vision in a validated zebrafish model, demonstrating neuroprotective and regenerative effects.

• Progeria & Werner Syndrome: In patient-derived Progeria (HGPS) cells, Telomir-1 normalized oxidative stress and mitochondrial instability. In nematode and zebrafish models of Werner-like accelerated aging, it extended lifespan, lengthened telomeres, reversed muscle degeneration, and reset molecular-age markers.

• Wilson’s Disease: In a genetic ATP7B-deficient (C271X⁻/⁻) zebrafish model, Telomir-1 produced dose-dependent restoration of neurological, hepatic, and renal function, reducing tremors four- to five-fold, halving hepatic copper accumulation, reversing liver and kidney pathology, normalizing ALT, AST, and bilirubin, and improving survival under copper stress.

• Type 2 Diabetes: In a zebrafish model of Type 2 diabetes mellitus, Telomir-1 reversed hyperglycemia and insulin resistance to near pre-diabetic levels, significantly reduced HOMA-IR values, improved oral glucose tolerance, and increased survival. Mechanistically, Telomir-1 appears to normalize iron metabolism and reduce oxidative stress in pancreatic beta cells, directly addressing the root cause of insulin resistance.

• Longevity & Healthspan: Using microfluidic C. elegans aging models developed with Nagi Bioscience SA, Telomir-1 extended lifespan, improved mobility, and reversed biological age markers, confirming its potential to enhance both longevity and healthspan.

Collectively, these data position Telomir-1 as a potential first-in-class DNA methylation reset and telomere stabilizing therapy with multi-system regenerative potential.

From a commercial perspective, unifying worldwide rights enables Telomir to access multi-hundred-billion-dollar opportunities. Global oncology spending alone is projected to exceed $400 billion by 2028 (IQVIA 2024), while the combined markets for AMD, diabetes, and neurodegenerative diseases surpass $1 trillion annually.

Key LOI Terms (Summary)

• Structure: Stock-for-stock acquisition; exchange ratio determined by independent valuation.

• Shareholder Contribution: A potential for up to $5 million in cash or cash equivalents over the duration of the collaboration- $1 million at closing; $2 million upon IND acceptance; $2 million upon Phase 1/2 initiation. Milestone shares allocated but not issued until funded.

• Lockup: TELI shareholders subject to a six-month lockup on shares received.

• Closing: Not contingent on milestone payments; subject to customary board, stockholder, regulatory, and due diligence conditions.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target epigenetic drivers of cancer, aging, and age-related disease. Its lead candidate, Telomir-1, has demonstrated the ability to reset DNA methylation, stabilize telomeres, inhibit histone demethylases, and restore cellular energy and metabolic balance across multiple preclinical models. For more information, visit www.telomirpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

Global fintech strengthens its presence in the Americas with launch aimed at empowering Mexico’s 4.5M+ small businesses

BOULDER, CO / ACCESS Newswire / October 21, 2025 / Global fintech SumUp today announced it has officially launched in Mexico, marking a significant milestone in its expansion across the Americas. SumUp is introducing its proven suite of digital payment and business tools to one of Latin America’s most dynamic small business markets, taking the next step in its mission to make commerce simple and accessible for all.

According to the World Bank and OECD, Mexico is home to almost 4.5 million small and medium businesses (SMBs), of which 94% are considered micro-businesses. These merchants are at the heart of Mexico’s economy – and precisely the types of businesses SumUp was founded to empower, making it effortless for small businesses to accept payments and thrive, wherever they are.

As part of the launch, SumUp has introduced the SumUp Go card reader to the Mexican market. A compact, user-friendly device, the Go card reader allows merchants to accept payments anytime, anywhere, with no monthly fixed costs. It’s compatible with all major credit and debit cards, with remarkable battery life and unlimited 4G cellular connectivity thanks to its built-in SIM. The Go is designed for durability and comes equipped with advanced security features, to deliver safe and compliant transactions.

“Expanding into Mexico marks a pivotal step in SumUp’s strategic growth across Latin America,” said Andrew Helms, CEO of SumUp North America. “We see remarkable potential in the region and recognize a strong demand for accessible, user-friendly payment solutions that streamline business operations. At SumUp, our mission is to simplify business for our merchants and we’re delighted to bring this commitment to Mexico.”

Mexico remains a largely cash-led economy, with just over a quarter of transactions conducted by card. Limited bank account penetration and low NFC adoption have historically slowed digital payments. However, recent trends show a growing preference for debit cards, signalling a shift towards cashless transactions, indicating this will increase in the next few years.

SumUp’s product development is built around merchant feedback. The company continuously evolves its ecosystem to meet the specific needs of each market. In Mexico, merchants will gain access to a growing suite of payment and financial tools designed to help them operate more efficiently and compete in an increasingly digital economy.

About SumUp

SumUp is a global financial technology company driven by the mission of empowering small businesses all over the world. Established in 2012, SumUp is the financial partner for more than 4 million entrepreneurs in over 35 markets worldwide. In the United States, SumUp offers an ecosystem of affordable, easy-to-use financial products, such as point-of-sale and loyalty solutions, kiosks, card readers, and invoicing.

For more information, please visit https://www.sumup.com

Contact Information

Kite Hill PR
sumup@kitehillpr.com

SOURCE: SumUp

View the original press release on ACCESS Newswire

Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA’s position in a $70 billion non-opioid pain market.

MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outperforming injected morphine in an established animal model of inflammatory pain.

This study marks the first time inflammation was directly measured alongside pain in MIRA’s Mira-55 program. In the Company’s prior study, only pain sensitivity was evaluated, with both Mira-55 and morphine administered by injection. The new data expand those findings by demonstrating that oral administration of Mira-55 provided superior pain normalization and direct anti-inflammatory effects, whereas morphine produced only partial and indirect inflammation reduction.

Study Overview and Key Findings

Pain sensitivity was assessed using Von Frey Filament testing, and inflammation was quantified by paw-edema volume in the formalin-induced inflammatory pain model.

Results:

• Oral Mira-55 normalized pain thresholds, fully restoring withdrawal responses to baseline and outperformed injected morphine.

• Mira-55 significantly reduced inflammation, confirming a direct CB2 receptor-mediated anti-inflammatory mechanism, while morphine showed only partial, centrally mediated effects.

• Both treatments provided pain relief, but Mira-55 delivered dual anti-inflammatory and analgesic benefits without sedation or opioid-related risks.

These findings build on previously reported data showing that injected Mira-55 achieved morphine-comparable pain relief, while this new study demonstrates that oral Mira-55 achieved superior pain normalization and direct inflammation reduction. Collectively, the results reinforce Mira-55’s potential as a dual-acting, non-opioid therapy that addresses both inflammation and pain through differentiated, CB2-selective mechanisms.

Reducing inflammation is fundamental to treating pain effectively. Inflammation drives the heightened sensitivity of pain-sensing nerves, amplifying pain signals. Traditional opioids only block pain perception in the brain and do not address inflammation, while NSAIDs treat inflammation but carry significant safety risks. By directly targeting inflammation through CB2 receptor activation, Mira-55 addresses both the cause and the perception of pain, offering a differentiated approach that could redefine how chronic inflammation-driven pain is managed.

Leadership Commentary

“These results highlight the strength of our pipeline and the potential of Mira-55 to become a next-generation, non-opioid therapy,” said Erez Aminov, CEO of MIRA. “With Mira-55 demonstrating meaningful anti-inflammatory and pain-modulating effects through oral administration, we believe MIRA is well positioned to advance multiple programs addressing some of the largest unmet needs in pain and neuroscience.”

Dr. Itzchak Angel, CSA at MIRA, added: “Oral Mira-55’s ability to normalize pain and directly suppress inflammation through CB2 activation highlights a major advance in cannabinoid-based therapeutics. These findings strengthen the rationale for moving this compound toward clinical development.”

Market Opportunity and Strategic Positioning

Chronic inflammatory pain remains one of the largest and most underserved therapeutic markets, historically dominated by NSAIDs and opioids that carry well-documented safety and dependency risks. Mira-55’s CB2-selective mechanism directly targets both pain and inflammation, offering a novel, non-opioid, non-NSAID alternative. The global non-opioid pain treatment market was valued at USD 45.3 billion in 2024 and is projected to reach USD 70.3 billion by 2030, growing at a CAGR of 7.7%. (Grand View Research, 2024)

Broader Preclinical Promise

Beyond its anti-inflammatory and analgesic profile, prior preclinical studies have shown that Mira-55 enhanced memory performance and reduced anxiety-related behavior, suggesting broader neurologic and neuropsychiatric potential.

About Mira-55

Mira-55 is a next-generation analog of marijuana engineered to selectively activate CB2 cannabinoid receptors associated with anti-inflammatory and analgesic effects while minimizing CB1-related psychoactivity. Following scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance, supporting its favorable regulatory profile and long-term commercial potential.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline includes Mira-55, a non-psychoactive cannabinoid analog for chronic inflammatory pain with additional preclinical evidence of anti-anxiety and memory-enhancing activity; Ketamir-2, an NMDA-receptor antagonist in development for neuropathic pain; and SKNY-1, an oral drug candidate targeting obesity and smoking cessation. The Company is headquartered in Miami, Florida.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

SASKATOON, SK / ACCESS Newswire / October 16, 2025 / Holistic Physiotherapy & Wellness has been recognised as a 2025 Consumer Choice Award recipient in the Physiotherapist category for Saskatoon. This marks the clinic’s second consecutive recognition, underscoring its reputation for collaborative, patient-centred care and its commitment to supporting health and well-being throughout the community.

Located in the heart of downtown Saskatoon, Holistic Physiotherapy & Wellness brings together a collaborative team across physiotherapy, chiropractic care, massage therapy, lifestyle medicine, dietetics, nutrition counselling, and more-all under one roof. The clinic’s whole-person approach goes beyond surface-level symptoms, uncovering root causes and empowering patients in their own care to reach their goals while supporting lasting recovery.

“At Holistic Physiotherapy & Wellness, we believe meaningful change in healthcare happens through collaboration, community, and caring for the whole person,” says Kim Deschamps, Founder & CEO. “Being named a Consumer Choice Award recipient for the second time reaffirms our mission to provide evidence-informed care that empowers people to live with strength, balance, and vitality.”

Supporting Health at Every Stage of Life

The clinic provides care for all ages and lifestyles, from newborns to seniors, athletes to everyday movers. By combining hands-on therapies with education, nutrition, and lifestyle support, Holistic Physiotherapy & Wellness helps patients reach their goals, recover from injuries, and maintain long-term health.

Patients value the clinic’s integrated approach, which brings together multiple disciplines to address both immediate concerns and overall well-being. This unique model ensures that each individual receives care tailored to their needs while honouring the interconnectedness of body, mind, and lifestyle.

This year’s recognition is especially meaningful for Holistic Physiotherapy & Wellness, as it reflects the trust patients place in their care team and the relationships built within the Saskatoon community. “This award is not just about our clinic, it is about the patients and families who inspire us every day,” adds Deschamps.

Moving Forward with Purpose

As Holistic Physiotherapy & Wellness celebrates its second Consumer Choice Award recognition, the clinic looks ahead to building even stronger connections within the community. By continuing to evolve its services, expand its team of health professionals, and invest in collaborative, whole-person healthcare, the clinic remains dedicated to guiding patients toward healthier, more fulfilling lives.

To learn more about Holistic Physiotherapy & Wellness or to book an appointment, visit www.holisticphysiowellness.ca or CLICK HERE.

About Holistic Physiotherapy & Wellness
Holistic Physiotherapy & Wellness is a Saskatoon-based clinic offering physiotherapy, chiropractic care, massage therapy, lifestyle medicine, dietetics, and nutrition counselling through a collaborative, multidisciplinary approach. Guided by the principles of whole-person care, the clinic looks beyond symptoms to uncover root causes and empower patients in their own care to reach their goals while supporting lasting recovery. Serving patients of all ages, the team helps individuals live with strength, balance, and vitality. Recognised as a two-time Consumer Choice Award recipient, Holistic Physiotherapy & Wellness continues to set the standard for collaborative, patient-centred care in the Saskatoon community. Learn more at www.holisticphysiowellness.ca.

About Consumer Choice Award
Since 1987, Consumer Choice Award has been recognising and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Advanced Lipedema Treatment (ALT)

LOS ANGELES, CA / ACCESS Newswire / October 15, 2025 / Advanced Lipedema Treatment (ALT) is proud to announce that Dr. David Smart has joined Dr. David Amron and Dr. Aria Vazirnia in offering in-network services with Aetna insurance. As one of ALT’s leading surgeons at The Roxbury Institute in Salt Lake City, UT, Dr. Smart is recognized for his expertise in dermatologic surgery and his dedication to treating women with lipedema. His patient-focused approach and surgical skill reflect ALT’s mission of delivering compassionate, high-quality care.

David Smart, M.D.
Fellowship-trained dermatologic surgeon and former Director of Cosmetic Dermatologic Surgery at the University of Utah, Dr. David Smart, is now in-network with Aetna insurance.

Lipedema, a chronic and painful fat disease affecting millions of women, continues to face significant challenges in recognition and insurance coverage. Despite its prevalence, most patients encounter barriers when seeking treatment, as the condition is too often excluded from traditional coverage policies. This lack of support has left many women struggling without access to effective surgical options. ALT has worked to bridge this gap by advocating for equitable coverage and expanding opportunities for patients to receive the care they deserve.

Aetna’s expanded coverage now gives patients greater access to the ALT method, developed by Dr. David Amron. With over 30 years of pioneering work in lipedema surgery, Dr. Amron has developed a comprehensive approach to provide effective treatment and prevention, while achieving the highest standards of care and outcomes for women worldwide.

“I’m honored to join the Aetna network and help expand access to lipedema surgery for the many women who need and deserve this care,” said Dr. David Smart. “Lipedema is a life-altering medical condition that warrants greater recognition and equitable access to proper surgical treatment. This milestone represents an important step toward ensuring that women affected by lipedema receive both the acknowledgment and the care they deserve.”

Dr. Smart’s in-network status with Aetna marks a significant step forward in ALT’s mission to expand access to advanced lipedema treatment and raise the standard of care for women nationwide. Rooted in Dr. Amron’s pioneering work and strengthened by the expertise of ALT’s surgical team, this milestone ensures that more patients than ever can access comprehensive treatment through the Aetna network.

Educated at the forefront of dermatology and cosmetic surgery, Dr. Smart graduated with honors from Brigham Young University before earning his medical degree from the Medical College of Wisconsin as a member of the Alpha Omega Alpha Honor Society. He completed his dermatology residency at the University of Illinois Chicago, followed by an aesthetic and surgical dermatology fellowship at the Center for Laser and Cosmetic Surgery in New York. He was then recruited by the University of Utah School of Medicine as Director of Cosmetic Dermatologic Surgery, where he became the first dermatologic surgeon in the department to perform liposuction, pioneering its tumescent technique and introducing Renuvion J-Plasma technology to Utah.

Dr. Smart is driven by a deep passion for helping patients with lipedema restore both their health and confidence. He completed an extensive fellowship in Lipedema Liposuction Surgery under the mentorship of Dr. David Amron at The Roxbury Institute in Beverly Hills, as part of the Advanced Lipedema Treatment program. During this fellowship, he mastered the innovative ALT method-Dr. Amron’s three-dimensional, lymphatic-sparing approach to liposuction for lipedema treatment.

With his specialized training, artistic eye, and unwavering dedication to patient care, Dr. Smart provides life-changing results while upholding the highest standards of compassion and integrity.

“Dr. David Smart’s expertise and compassion reflect the core values of our mission at Advanced Lipedema Treatment,” said Dr. David Amron, Founder and Medical Director of The Roxbury Institute. “His dedication to expanding access to care for women living with lipedema represents a powerful step forward in our ongoing commitment to awareness, advocacy, and equitable insurance coverage. Having him join the Aetna network ensures that even more patients can receive the comprehensive, life-changing treatment they deserve.”

The Advanced Lipedema Treatment Program at The Roxbury Institute embodies the culmination of Dr. Amron’s pioneering work and ALT’s mission to provide women with lipedema worldwide access to life-changing treatment, restoring both health and confidence through advanced surgical care.

To learn more about Dr. Smart, treatment options, or schedule a consultation with a lipedema expert, patients and referring physicians are invited to visit: www.AdvancedLipedemaTreatment.com.

Contact Information:

Natalia Y. Grazziani
Public Relations for Dr. David Amron
natalia@grazzianicommunications.com
323-646-1581

SOURCE: The Roxbury Institute

View the original press release on ACCESS Newswire